Pulmonary function parameters in patients with diabetes mellitus

Özmen, Bilgin; Çeli̇k, Pınar; Yorgancıoğlu, Arzu; Özmen, Dilek; Çok, Gürsel

doi:10.1016/s0168-8227(02)00057-8

Cited by 13 publications

(14 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[6][7][8][9] It should be noted that some studies found no association between lung function and the presence of DM. [10][11][12] Our study did not fi nd differences in FVC, FEV1, FEV6, PEF, FEF2575 and FEV3 according to the presence of DM with FVC difference between the groups being almost signifi cant. There is no difference in the prevalence of DM in patients with FEV1 < 50%, when compared to patients with FEV1 > 50% or regarding GOLD stage.…”

Section: Discussioncontrasting

confidence: 50%

See 1 more Smart Citation

Diabetes Mellitus Type 2 in Hospitalized COPD Patients: Impact on Quality of Life and Lung Function

Mekov¹,

Slavova²,

Genova³

et al. 2016

Folia Medica

View full text Add to dashboard Cite

Introduction: Diabetes mellitus (DM) is estimated to affect 2-37% of COPD patients, results varying widely between studies. DM may also correlate with quality of life and lung function. Aim: To examine correlations between DM and quality of life and lung function in COPD patients admitted to hospital with exacerbation of COPD. Patients and methods: A hundred and fifty-two patients were included in the study. They were all examined for diabetes mellitus. All patients completed CAT and mMRC questionnaires and underwent spirometry. Results: 13.2% (20/152) of patients received medications for DM. 21.7% (33/152) had newly diagnosed DM and 30.9% (47/152) had prediabetes. DM is not associated with reduced quality of life and worse pulmonary function. However, untreated DM is associated with both reduced quality of life and worse pulmonary function. HbA1c is negatively correlated with FVC and positively correlated with CAT score. Conclusions: COPD patients hospitalized for exacerbation are at high risk for impaired glucose metabolism. Untreated DM is associated with worse lung function and lower quality of life, which stresses the importance of screening for the disease. The patients may benefit from optimizing blood glucose level.

show abstract

Section: Discussioncontrasting

confidence: 50%

“…However, some studies found no association between lung function and the presence of DM. [10][11][12] There are not enough data to determine whether the results from these studies are applicable to specifi c subgroups of patients such as COPD patients admitted for exacerbation.…”

Section: Introductionmentioning

confidence: 99%

Diabetes Mellitus Type 2 in Hospitalized COPD Patients: Impact on Quality of Life and Lung Function

Mekov¹,

Slavova²,

Genova³

et al. 2016

Folia Medica

View full text Add to dashboard Cite

show abstract

“…The authors suggested seated and supine measures of CO transfer capacity to diagnose early pulmonary vascular damage in diabetes. Accordingly, Ozmen et al (15) noted that their failure to show a relationship between CO transfer capacity and microalbuminuria, diabetes duration, or glycemic control was most likely due to relative insensitivity of the usual clinical method of measuring CO transfer capacity.…”

mentioning

confidence: 99%

Lung Dysfunction in Diabetes

Goldman

2003

Diabetes Care

112

View full text Add to dashboard Cite

“…125,138 However, further cross-sectional case-control studies with relatively small numbers of patients have produced conflicting results. While some have shown significant reduction in lung volumes compared with controls, [139][140][141][142] others failed to show significant differences in spirometry between patients with diabetes and normal control subjects, 124,143 differences from normal population-predicted values, 144 or a relationship with diabetes control 145 or duration of disease. 146,147 The nature of pulmonary function abnormalities in patients with diabetes in these studies was also inconsistent.…”

Section: Clinical Studies Of Lung Function In Diabetesmentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation

Black¹,

Cummins²,

Royle³

et al. 2007

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTAThe clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, now part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the costs, effectiveness and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggest...

show abstract

Pulmonary function parameters in patients with diabetes mellitus

Cited by 13 publications

References 9 publications

Diabetes Mellitus Type 2 in Hospitalized COPD Patients: Impact on Quality of Life and Lung Function

Diabetes Mellitus Type 2 in Hospitalized COPD Patients: Impact on Quality of Life and Lung Function

Lung Dysfunction in Diabetes

The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation

Contact Info

Product

Resources

About